Article
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
International journal of oncology - 1 Jun 2020
Bombac Alenka, Zakotnik Branko, Bucic Marina, Setrajcic Dragos Vita, Gazic Barbara, Stegel Vida, Klancar Gasper, Novakovic Srdjan
Abstract excerpt
In total, ~85% of malignant gastrointestinal stromal tumours (GISTs) harbour activating mutations in one of the genes KIT or PDGFRA, while 10‑15% of all GISTs have no detectable KIT or PDGFRA mutations, but could have alterations in genes of the succinate dehydrogenase complex or in BRAF, PIK3CA or rarely RAS family genes. The clinical benefit of tyrosine kinase inhibitors, such as imatinib, depends on the GIST...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.